(1S,4R)-4-[3-((S)-2-Methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine → Methanesulfonic acid 2-[3-isopropyl-5-(3-{(1S,4R)-4-[3-((S)-2-methyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-[1,4']bipyrazolyl-1'-yl]-ethyl ester

HRID 2200024Notes

Reaction equation

HRID 2200024 reaction equation
C[C@H]1CCCCN1C1N2C=C(O[C@H]3C4C(=CC=CC=4)[C@@H](N)CC3)C=CC2=NN=1.[CH3:29][C@H:30]1[CH2:35][CH2:34][CH2:33][C@@H:32](C)[N:31]1[C:37]1[N:41]2[CH:42]=[C:43]([O:46][C@H:47]3[C:56]4[C:51](=[CH:52][CH:53]=[CH:54][CH:55]=4)[C@@H:50]([NH:57][C:58](=[O:80])[NH:59][C:60]4[N:64]([C:65]5[CH:66]=[N:67][N:68]([CH2:70][CH2:71][O:72][S:73]([CH3:76])(=[O:75])=[O:74])[CH:69]=5)[N:63]=[C:62]([CH:77]([CH3:79])[CH3:78])[CH:61]=4)[CH2:49][CH2:48]3)[CH:44]=[CH:45][C:40]2=[N:39][N:38]=1>>[CH:77]([C:62]1[CH:61]=[C:60]([NH:59][C:58]([NH:57][C@@H:50]2[C:51]3[C:56](=[CH:55][CH:54]=[CH:53][CH:52]=3)[C@H:47]([O:46][C:43]3[CH:44]=[CH:45][C:40]4[N:41]([C:37]([N:31]5[CH2:32][CH2:33][CH2:34][CH2:35][C@@H:30]5[CH3:29])=[N:38][N:39]=4)[CH:42]=3)[CH2:48][CH2:49]2)=[O:80])[N:64]([C:65]2[CH:66]=[N:67][N:68]([CH2:70][CH2:71][O:72][S:73]([CH3:76])(=[O:75])=[O:74])[CH:69]=2)[N:63]=1)([CH3:78])[CH3:79]

Participants

3

Procedure

The title compound was prepared starting from Intermediate 2 (150 mg, 0.397 mmol), and Intermediate Ac (163 mg, 0.397 mmol) by using an analogous procedure to that described for Intermediate A step d. LCMS (Method 3): Rt 3.21 min, m/z=639 [MH+].

Sources & evidence

ORD record
ord-b3ccf013ca0740508fcdb569af658214
Source dataset
uspto-grants-2016_06
Patent number
US09359354B2

Reaction notes

Loading…